Urinary Vitronectin Biomarker for Kidney Fibrosis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for renal damage, particularly kidney fibrosis in transplanted kidneys, are invasive, non-specific, and lack sensitivity, leading to misdiagnosis and limited treatment options for early fibrosis detection.
Innovation Solution
Utilization of vitronectin (VTN) protein levels in urine as a non-invasive biomarker to detect and differentiate the degree of kidney fibrosis, allowing for early identification of moderate to severe fibrosis and guiding treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If kidney biopsy is performed to diagnose renal fibrosis, then diagnostic accuracy is improved, but patient morbidity and treatment complexity increase due to invasiveness
Solution Approach 1:
The patent uses urinary vitronectin as an intermediary biomarker that reflects kidney fibrosis status without requiring direct tissue sampling. Vitronectin levels in urine correlate with fibrosis severity, serving as a non-invasive proxy for the pathological state that would otherwise require biopsy to assess
Solution Approach 2:
The patent replaces the mechanical invasive procedure of kidney biopsy with a biochemical measurement of urinary vitronectin. This substitution eliminates the physical trauma associated with needle puncture and tissue extraction while maintaining diagnostic information through molecular analysis
2Measurement precision
If kidney biopsy is performed to assess fibrosis degree, then diagnostic precision is improved, but procedure complexity and risk increase
Solution Approach 1:
The patent replaces the complex mechanical procedure of kidney biopsy with a simple urinary biomarker measurement. Instead of requiring tissue extraction, processing, and histological analysis, the diagnosis is achieved through measuring vitronectin concentration in urine using standard biochemical assays
Solution Approach 2:
Urinary vitronectin serves as an intermediary that carries information about kidney fibrosis status from the deep tissue environment to the accessible urinary tract, allowing indirect but accurate assessment of fibrosis without direct tissue sampling
3Ease of operation
If current markers like creatinine are used for monitoring, then ease of measurement is maintained, but early detection capability and sensitivity deteriorate
Solution Approach 1:
The patent changes the measured parameter from non-specific markers like creatinine to the specific biomarker vitronectin, which exhibits altered levels in response to early fibrotic changes. This parameter change enables detection of pathological processes at earlier stages while maintaining the simplicity of urinary measurement
4Measurement precision
If frequent monitoring is performed to detect early fibrosis, then detection sensitivity is improved, but patient burden and resource use increase with invasive procedures
Solution Approach 1:
The patent replaces repeated invasive biopsy procedures with frequent but harmless urinary measurements. The simplicity of urine collection allows for longitudinal monitoring without subjecting patients to repeated surgical risks, enabling early detection while minimizing patient burden
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
The present invention relates to urine protein markers of renal damage or pathological phenotype and methods using thereof. It further relates to urine protein markers for determining the degree of fibrosis in a kidney and methods using thereof. In particular, it relates to methods using said biomarkers in monitoring patient's suffering from chronic kidney disease or further to renal transplantation. It further pertains to associated second medical uses, methods of treatment, kits and use thereof in the methods of the invention.